DelveInsight’s ‘Non-small Cell Lung Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Non-small cell lung cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-small cell lung cancer pipeline domain.
For Non-small cell lung cancer emerging drugs, the Non-small cell lung cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Non-small Cell Lung Cancer (FTD) Pipeline Report
- Over 150+ Non-small cell lung cancer pipeline therapies are in various stages of development, and their anticipated acceptance in the Non-small cell lung cancer market would significantly increase market revenue.
- Leading Non-small cell lung cancer companies developing novel drug candidates to improve the Non-small cell lung cancer treatment landscape include BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
- Promising Non-small cell lung cancer pipeline therapies in various stages of development include INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
- In Oct 2022, BerGenBio announced that they had begun the phase Ib/IIa trial evaluating bemcentinib in first-line non-small cell lung cancer patients with STK11 mutations.
- In Oct 2022, eftilagimod alpha has been given a fast-track designation by the FDA for use as the first-line treatment for patients with stage IIIB/IV non-small cell lung cancer when combined with pembrolizumab.
- In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) entered an exclusive license agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398, was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
Request a sample and discover the recent breakthroughs happening NSCLC pipeline landscape in @ Non-small Cell Lung Cancer Pipeline Report
Non-small Cell Lung Cancer Overview
About 85% of all cases of lung cancer are non-small-cell lung cancer (NSCLC), which includes all epithelial lung cancers besides small-cell lung cancer (SCLC). NSCLC tumors come in three different varieties: a) Adenocarcinoma begins in cells that produce mucus and other substances inside air sacs, frequently in the outer regions of your lungs. It is the most prevalent form of lung cancer in people under 45 who smoke, nonsmokers, and both.
The common NSCLC symptoms include chest pain, wheezing, weight loss, shortness of breath, coughing up blood, and others. Several imaging tests such as X-ray, MRI, PET Scans, CT Scans, and others are used for NSCLC diagnosis. Apart from imaging tests, other tests used for NSCLC diagnosis include sputum cytology, bronchoscopy, and mediastinoscopy.
Non-small Cell Lung Cancer Pipeline Analysis: Drug Profile
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Datopotamab deruxtecan is one of three leading ADCs in Daiichi Sankyo’s oncology pipeline and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is made up of a humanized anti-TROP2 IgG13 monoclonal antibody developed in collaboration with Sapporo Medical University, which is linked to several topoisomerases I inhibitor payloads, an exatecan derivative via tetrapeptide-based cleavable linkers.
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized for long-term target inhibition, which may be important in treating KRASG12C-mutated cancers because the KRASG12C protein regenerates every 24-48 hours. Adagrasib is being tested in patients with advanced KRASG12C-mutated solid tumors, such as NSCLC, colorectal cancer, and pancreatic cancer, as a monotherapy and in combination with other anti-cancer therapies.
Non-small Cell Lung Cancer Pipeline Therapies and Key Companies
- Datopotamab deruxtecan: Daiichi Sankyo
- JDQ443: Novartis
- MRTX849: Mirati Therapeutics
- INBRX-106: Inhibrx
- GB 1211: Galecto Biotech
- BBP 398: BridgeBio Pharma
- TGRX 326: Shenzhen TargetRx
- SRF388: Surface Oncology
- ABBV 514: AbbVie
Learn more about the NSCLC emerging pipeline therapies @Non-small Cell Lung Cancer Clinical Trials
Non-small Cell Lung Cancer Pipeline Therapeutics Assessment
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Antisense oligonucleotide
- Gene therapy
- Small Molecule
Scope of the Non-small Cell Lung Cancer Pipeline Report
- Coverage: Global
- Key Non-small Cell Lung Cancer Companies: BridgeBio Pharma (NASDAQ: BBIO), Daiichi Sankyo, EMD Serono (ETR: MRK), Merck (NYSE: MRK), Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), BioNTech SE (NASDAQ: BNTX), Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer (ETR: BAYN), GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene (ASX: IMU), Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb (NYSE: BMY), Surface Oncology (NASDAQ: SURF), Inhibrx (NASDAQ: INBX), Sinocelltech, Mirati Therapeutics (NASDAQ: MRTX), REVOLUTION Medicines (NASDAQ: RVMD), Yong Shun Technology Development, Iovance Biotherapeutics (NASDAQ: IOVA), Galecto Biotech (NASDAQ: GLTO), and others.
- Key Non-small Cell Lung Cancer Pipeline Therapies: INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
Dive deep into rich insights for NSCLC emerging therapies and assessment, visit @ Non-small Cell Lung Cancer Emerging Therapies
Table of Contents
|5.||Late Stage Products (Phase III)|
|6.||Mid Stage Products (Phase II)|
|7.||Early Stage Products (Phase I/II)|
|8.||Preclinical Stage Products|
|9.||Discovery Stage Products|
|12.||Collaborations Assessment- Licensing / Partnering / Funding|
|14.||Market Drivers and Barriers|
For further information on the NSCLC current pipeline therapeutics, reach out @ Non-small Cell Lung Cancer Therapeutics Assessment
Non-Small Cell Lung Cancer (NSCLC) Market
DelveInsight’s ‘Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast – 2032’ report delivers an in-depth understanding of Non-Small Cell Lung Cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key Non-Small Cell Lung Cancer companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.
Small-cell Lung Cancer Pipeline
Small-cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Small Cell Lung Cancer companies involved such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.
DelveInsight’s “Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market trends, and key Small Cell Lung Cancer companies involved such as Bristol-Myers Squibb, Merck, AstraZeneca, PharmaMar, EpicentRx, and many others.
“DelveInsight’s ‘Artificial Lung Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Artificial Lung and the historical and forecasted Artificial Lung market trends, and key players involved such as Xenios, Miromatrix Medical, Lung Biotechnology PBC, Haemair, Michigan Critical Care Consultants, MedArray, Breethe, ALung Technologies, McGowan Institute for Regenerative Medicine, and The Charles Stark Draper Laboratory.
Extensive Stage Small Cell Lung Cancer Pipeline
DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key Extensive Stage Small Cell Lung Cancer companies such as Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd, Celgene, and others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
- Small Cell Lung Cancer Treatment Market
- Global Healthcare Burden NSCLC Poses
- Lung Cancer and its Increasing Global Burden
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn